<DOC>
	<DOCNO>NCT03072901</DOCNO>
	<brief_summary>The purpose registry observe safety effectiveness outcomes subject treat EndoBarrier post market set product Conformité Européene ( CE mark ) regulatory approval accordance approve Indication For Use .</brief_summary>
	<brief_title>Registry Observing EndoBarrier® Treatment Outcomes Subjects With Type 2 Diabetes and/or Obesity</brief_title>
	<detailed_description>This worldwide observational registry use EndoBarrier inclusion subject treat EndoBarrier center Australia , Chile , Netherlands . The registry open subject participate center receive EndoBarrier .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Obesity</mesh_term>
	<criteria>As per IFU , EndoBarrier GI liner System use treatment obese type 2 diabetes BMI great equal 30 kg/m2 , obese patient BMI great equal 30 kg/m2 less equal 1 comorbidities , obese patient BMI great 35 kg/m2 . The GI liner indicate maximum implant duration 12 month . As per Instructions For Use ( IFU ) Women pregnant Requirement prescription anticoagulation therapy History inflammatory bowel disease condition gastrointestinal tract , peptic ulcer disease ( PUD ) , ulcer , Crohn 's disease Pancreatitis , Uncontrolled gastroesophageal reflux disease ( GERD ) , Known infection time implant Symptomatic coronary artery disease pulmonary dysfunction History coagulopathy Bleeding diathesis , upper GI bleeding condition esophageal gastric varix , congenital acquire intestinal telangiectasia Congenital acquire anomaly GI tract atresias stenosis Previous GI surgery could affect ability place EndoBarrier Gastrointestinal Liner function Iron deficiency and/or iron deficiency anemia Active symptom kidney stone know presence gallstone Inability discontinue use nonsteroidal antiinflammatory drug implant period Family patient history know diagnosis preexist condition systemic lupus erythematosus , scleroderma , autoimmune connective tissue disorder H. pylori positive status ( Patients may receive EndoBarrier Gastrointestinal Liner prior history successfully treat )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>